Participated · Series B · Feb 2025

Newronika develops an adaptive deep brain stimulation (DBS) platform that integrates real-time patient neural data and machine learning to optimize therapy and reduce side effects. The company holds a CE Mark and has received an Investigational Device Exemption (IDE) from the FDA, and recently received a grant from The Michael J. Fox Foundation. The €13.6 million Series B financing will accelerate clinical validation and commercialization of its proprietary adaptive DBS system. Newronika plans to advance its product pipelines, recruit top-tier talent, and establish strategic collaborations to strengthen its position at the intersection of medical device engineering and neuroscience. Headquartered in Milan, Italy, the company positions its technology as a next-generation personalized neuromodulation solution. The funding supports Newronika's push toward broader clinical and commercial deployment. Newronika develops an adaptive deep brain stimulation (DBS) system, the Alpha-DBS, designed to automatically adjust therapy to patients’ needs. The company has a CE-marked deep brain stimulation system and is developing proprietary adaptive DBS technology with licensed patents and published initial clinical data. The €2.5M EIC Accelerator grant will fund a multi-center European pivotal trial comparing adaptive DBS to conventional DBS in advanced Parkinson’s disease patients and support product development for European market readiness. Newronika was founded in 2009 by a multidisciplinary team led by Dr. Alberto Priori with participation from Fondazione IRCCSS Ca’ Granda Ospedale Maggiore Policlinico and the University of Milan. The company is venture-backed and is completing feasibility trials at several leading DBS centers. Its platform technology is positioned for application to other central nervous system disorders. Newronika is a Milan-based neurotech startup that has developed an implantable medical device for deep brain stimulation using a retroaction “closed loop” system. The company's technology is initially targeted at patients affected by Parkinson’s disease. Newronika is a spin-off of Policlinico di Milano and Università degli Studi di Milano and is led by CEO Lorenzo Rossi and CFO Alain Garcinuño. It raised €8.4m in funding to advance its clinical and regulatory work. Proceeds will be used to complete its first human clinical study and to obtain CE marking and IDE acknowledgement from the FDA. The company says it is ready to start the clinical experiment to make the technology available to patients. Newronika develops a patented closed‑loop Deep Brain Stimulation (DBS) technology that records brain activity and modulates neurostimulation based on Parkinson’s fluctuations and patient conditions. The company’s core product is an implantable device for neuromodulation therapy aimed at treating Parkinson’s disease. Newronika is a spin‑off from Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano and Università degli Studi di Milano. It has completed a first human feasibility and safety study involving 17 patients, with results to be released soon. The firm intends to use newly raised funds to continue clinical studies, finalize development of its implantable device and complete the regulatory clinical path. The company holds patented technology developed from research by Prof. Alberto Priori and Lorenzo Rossi, PhD.

Participated · Series B · Jul 2022

Erydel is a drug delivery company specialized in delivery through autologous red blood cells. Its core approach uses patients' own red blood cells as a vehicle to deliver therapeutics. The company completed a €15m Series B financing. The round was led by Genextra S.p.A. Existing investors Innogest SGR and Focus Gestioni SGR also participated in the financing. Torch Partners acted as exclusive financial advisor to Erydel on the transaction. EryDel develops a proprietary device that encapsulates drugs into a patient’s own red blood cells for re-infusion, targeting rare neurodegenerative disorders. Its lead product, EryDex, has received Orphan Drug designation from both the FDA and the EMA for Ataxia Telangiectasia (AT). The company is advancing a registrational Phase III trial (ATTEST) that is currently enrolling in Europe, Asia, Australia and the United States. EryDel plans to use new funding to boost its international development and to complete the ATTEST trial. The company is led by CEO Luca Benatti, a serial entrepreneur who co-founded Newron Pharmaceuticals. EryDel is based in Milan, Italy.

Led · Series B · Apr 2021

GreenBone Ortho SpA develops bio-inspired, off-the-shelf 3D bone grafts built from natural wood-derived scaffolds incorporating resorbable nano-crystalline hydroxyapatite, beta-tricalcium phosphate, magnesium and strontium. The cell-free, growth-factor-free scaffold is highly porous and has demonstrated the ability to drive de novo bone mineralisation at ectopic sites; two international clinical studies are ongoing and a CE-mark was granted in December 2019 for a portfolio addressing large segmental bone defects. The company plans to use the new funding to expand clinical indications such as spinal and maxillofacial surgery, build a new production line, and support the market launch of the approved product. GreenBone has raised EUR22 million in equity since its 2015 founding in Faenza, Italy, including the EUR10 million Series B just closed. The technology aims to offer an alternative to traditional bone grafts and transplants by mimicking natural bone chemistry and 3D architecture to improve outcomes for large bone replacements. Management and the new board include experienced investors and industry executives who will support clinical and commercial roll-out. GreenBone, founded in 2014 and based in Faenza, Italy, develops a patented wood-derived, biomimetic and resorbable scaffold for bone regeneration targeting long-bone non-unions, spinal damage, trauma and cancer-induced bone loss. Its core product is a bio-inspired bone implant designed to regenerate functional bone and reduce healthcare and social costs for patients with severe skeletal damage. The company has completed pre-clinical studies in cooperation with Assaf-Harofeh Hospital and the Rizzoli Orthopedic Institute and holds granted patents in the USA, EU, China and other countries with a PCT application pending. GreenBone intends to complete clinical development in load-bearing long-bone defects and pursue CE marking, while also conducting pre-clinical development for additional skeletal applications. Financially, the company closed a €3 million seed round in 2015 and has secured a €2 million investment from Helsinn Investment Fund as part of a wider fundraising. Management is described as experienced and having advanced multiple orthopedic products from bench to market. GreenBone develops a wood-derived bone implant technology designed to generate biomimetic, reabsorbable load-bearing implants suitable for addressing non-union fractures. The implant concept was conceived and developed by a research group at ISTEC-CNR (Andrea Ruffini, Simone Sprio and Anna Tampieri). The company plans to continue platform development, run clinical studies on patients with bone damages and obtain the CE mark. GreenBone is an Innovative Startup under Italian law. In its first venture capital funding the company raised €3m to support those development and regulatory efforts. The company was founded in 2014 and is based in Faenza, Italy.

Participated · Series C · Mar 2021

Founded in 2014, Everli operates a home-delivery grocery marketplace focused on convenience and time savings for Italian consumers. In addition to delivery, the company leverages its platform data to offer analytics and market research to large grocery retailers and FMCG brands, helping them make more informed commercial decisions. Everli reports growing order volumes, larger basket sizes, and improving unit economics as it scales in its core geographies. The company’s strategy centers on expanding share across Italy, broadening product assortment, and deepening collaborations with leading European retailers. Recent initiatives also include continued investment in technology and operational efficiency. Looking ahead, Everli plans to combine with Melar Acquisition Corp I and targets a public listing in the first quarter of 2026, using fresh capital to fund this trajectory.

Participated · Equity · Feb 2021

MedLumics is developing an optically-guided real-time ablation catheter that displays lesion creation in real time to give physicians direct visual confirmation of conduction tissue denaturation. The company achieved pre-clinical feasibility in 2020. Proceeds from the recent financing will enable MedLumics to initiate first-in-human regulatory clinical studies and to automate scalable product manufacturing. MedLumics also operates Medlumics Ireland Ltd., a subsidiary focused on automated optical sensor and packaging processes for high-volume manufacture. The company is led by CEO James Greene and has appointed Rich Ferrari as Chairman of the Board, with Olivier Litzka of Andera Partners moving to Vice Chairman. The business is based in Madrid, Spain. MedLumics develops optically guided medical devices based on a proprietary integrated optics platform that enables miniature multiview optical probes and portable OCT systems. Its lead product, the AblaView catheter, is designed to provide direct, real-time information on lesion formation around a radiofrequency electrode to improve safety and efficacy of atrial fibrillation and other arrhythmia ablations. The company is completing development of a clinical version with a 360-degree real-time view of tissue and plans international clinical trials to prove safety and efficacy. MedLumics intends to market the device to specialist centers and expand and develop its team internationally. Founded in 2009 and ISO13485 certified, the company positions its technology as a way to reduce pulmonary vein reconnection and recurrence after ablation. It recently closed significant Series B financing to advance product and clinical development. MedLumics develops a compact microchip-based optical coherence tomography (OCT) imaging platform. Its proprietary platform integrates optical and electrical OCT components on a microchip to produce dynamic, real-time, high-resolution diagnostic images with tissue penetration up to two millimeters. The technology is designed to enable a non-invasive "optical digital biopsy" that reduces procedure time, avoids damage to vulnerable structures, and expands OCT mobility within healthcare settings while lowering maintenance and production costs versus first-generation systems. Initial clinical applications will focus on dental implantology and intravascular imaging in cardiology, with potential use in oncology and other specialties. MedLumics announced a €3.5M ($4.7M) Series A to complete platform development and recruit executive and technical teams.